Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study.

British journal of haematology - 1 Nov 2014

Brunner-Ziegler Sophie, Jilma Bernd, Magirr Dominic, Sunder-Plassmann Raute, Giurgea Georgiana-Aura, Hammer Alexandra, Margeta Christian, Brunner Martin, Koppensteiner Renate, Mannhalter Christine

Abstract excerpt

Interindividual variations in dose requirements of oral vitamin K antagonists (VKA) are attributed to several factors, including genetic variant alleles of vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9), but also interaction with co-medications. In this context, proton pump inhibitor (PPI)-related alterations of VKA maintenance dose requirements have been published. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Pilot Projects

Share to Proton Pump Inhibitors

Share to Thrombosis

Share to Vitamin K

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 25142093
DOI: 10.1111/bjh.13082

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study.PMID 25142093Read ↗

[Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy].Semantic proximity Read ↗

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.Semantic proximity Read ↗

Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.Semantic proximity Read ↗

[The pharmacogenetics of vitamin K antagonists: still a matter for discussion].Semantic proximity Read ↗

[Pharmacogenomics of vitamin K antagonists].Semantic proximity Read ↗

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.Semantic proximity Read ↗

Pharmacogenetic tests could be helpful in predicting of VKA maintenance dose in elderly patients at treatment initiation.Semantic proximity Read ↗

VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patientsSemantic proximity Read ↗

The effects of CYP2C9 and VKORC1 gene polymorphisms on warfarin maintenance dose in Turkish cardiac patients.Semantic proximity Read ↗

Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin.Semantic proximity Read ↗

[Oral anticoagulation and pharmacogenetics: importance in the clinical setting].Semantic proximity Read ↗

[Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.